Riley Hampsch

Senior Associate at PAREXEL Consulting


HB 7962


  • B.S. Washington & Lee University
  • Ph.D. '18, Cancer Biology, Pharmacology and Molecular Therapeutics, Dartmouth College

Selected Publications

  • Hampsch R.A, Shee K, Bates D, Lewis L.D, Desire L, Leblond B, Demidenko E, Stefan K, Huang Y.H, Miller T.W. Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer. Oncotarget. 2017 Mar 28;8(13):21806-21817. 

  • Shee K, Yang W, Hinds JW, Hampsch RA, Varn FS, Traphagen NA, Patel K, Cheng C, Jenkins NP, Kettenbach AN, Demidenko E, Owens P, Faber AC, Golub TR, Straussman R, Miller TW.Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. J Exp Med. 2018 Mar 5;215(3):895-910. 

Speaking Engagements

  • Tumor Metabolism Keystone Symposium- Snowbird, UT  2018

  • Cancer Molecular Therapeutics Conference – Burlington, VT  2017

  • National Cancer Research Institute Conference (NCRI)- Liverpool, UK  2017

  • Cancer Molecular Therapeutics Conference – Seattle, WA 2016

  • San Antonio Breast Cancer Symposium (SABCS)- San Antonio, TX  2015 & 2016

  • Awards

    NCRI Conference Travel Award, National Cancer Research Institute, 2017

    SABCS Basic Science Scholar Award, San Antonio Breast Cancer Symposium, 2016

  • Laboratory

    Miller Lab